Home Angiogenesis Src 억제제 Saracatinib (AZD0530)

연구용

Saracatinib (AZD0530) Src 억제제

제품 번호S1006

Saracatinib (AZD0530)은 세포가 없는 분석에서 IC50 2.7 nM을 갖는 강력한 Src 억제제이며, c-Yes, Fyn, Lyn, Blk, Fgr 및 Lck에 강력하며; Abl 및 EGFR (L858R 및 L861Q)에는 덜 활성적입니다. autophagy를 유도하며 2/3상에 있습니다.
Saracatinib (AZD0530) Src 억제제 Chemical Structure

화학 구조

분자량: 542.03

바로가기

품질 관리

배치: 순도: 99.99%
99.99

세포 배양, 처리 및 작업 농도

세포주 분석 유형 농도 배양 시간 제형 활성 설명 PMID
CTV-1 Growth Inhibition Assay IC50=0.06143 μM SANGER
LAMA-84 Growth Inhibition Assay IC50=0.1599 μM SANGER
MEG-01 Growth Inhibition Assay IC50=0.23688 μM SANGER
EM-2 Growth Inhibition Assay IC50=0.265 μM SANGER
TE-15 Growth Inhibition Assay IC50=0.27412 μM SANGER
NCI-H1648 Growth Inhibition Assay IC50=0.28116 μM SANGER
TE-12 Growth Inhibition Assay IC50=0.3268 μM SANGER
LB996-RCC Growth Inhibition Assay IC50=0.44196 μM SANGER
K-562 Growth Inhibition Assay IC50=0.44967 μM SANGER
D-336MG Growth Inhibition Assay IC50=0.50304 μM SANGER
NOS-1 Growth Inhibition Assay IC50=0.60529 μM SANGER
EW-24 Growth Inhibition Assay IC50=0.62693 μM SANGER
BV-173 Growth Inhibition Assay IC50=0.65249 μM SANGER
NCCIT Growth Inhibition Assay IC50=0.73218 μM SANGER
NCI-H1436 Growth Inhibition Assay IC50=0.79049 μM SANGER
BB30-HNC Growth Inhibition Assay IC50=0.86203 μM SANGER
TE-8 Growth Inhibition Assay IC50=0.87275 μM SANGER
A704 Growth Inhibition Assay IC50=0.8921 μM SANGER
TK10 Growth Inhibition Assay IC50=0.90669 μM SANGER
KS-1 Growth Inhibition Assay IC50=1.19779 μM SANGER
C2BBe1 Growth Inhibition Assay IC50=1.20507 μM SANGER
RXF393 Growth Inhibition Assay IC50=1.2436 μM SANGER
KGN Growth Inhibition Assay IC50=1.27687 μM SANGER
NB69 Growth Inhibition Assay IC50=1.37497 μM SANGER
TE-11 Growth Inhibition Assay IC50=1.43418 μM SANGER
TE-1 Growth Inhibition Assay IC50=1.44105 μM SANGER
ST486 Growth Inhibition Assay IC50=1.45852 μM SANGER
HOP-62 Growth Inhibition Assay IC50=1.50246 μM SANGER
EW-16 Growth Inhibition Assay IC50=1.55083 μM SANGER
LB1047-RCC Growth Inhibition Assay IC50=1.55453 μM SANGER
TE-10 Growth Inhibition Assay IC50=1.66252 μM SANGER
RL95-2 Growth Inhibition Assay IC50=1.66902 μM SANGER
DOHH-2 Growth Inhibition Assay IC50=1.71782 μM SANGER
MFH-ino Growth Inhibition Assay IC50=1.7787 μM SANGER
GB-1 Growth Inhibition Assay IC50=1.79833 μM SANGER
SK-N-DZ Growth Inhibition Assay IC50=1.84688 μM SANGER
OS-RC-2 Growth Inhibition Assay IC50=1.88574 μM SANGER
SW982 Growth Inhibition Assay IC50=1.92093 μM SANGER
KALS-1 Growth Inhibition Assay IC50=1.98722 μM SANGER
TGBC24TKB Growth Inhibition Assay IC50=2.05958 μM SANGER
GI-1 Growth Inhibition Assay IC50=2.16084 μM SANGER
SW962 Growth Inhibition Assay IC50=2.17178 μM SANGER
SW872 Growth Inhibition Assay IC50=2.18507 μM SANGER
NCI-H747 Growth Inhibition Assay IC50=2.25714 μM SANGER
MZ1-PC Growth Inhibition Assay IC50=2.29356 μM SANGER
MSTO-211H Growth Inhibition Assay IC50=2.35723 μM SANGER
BL-70 Growth Inhibition Assay IC50=2.47422 μM SANGER
SW954 Growth Inhibition Assay IC50=2.57408 μM SANGER
SNB75 Growth Inhibition Assay IC50=2.68594 μM SANGER
IST-SL2 Growth Inhibition Assay IC50=2.72379 μM SANGER
GCIY Growth Inhibition Assay IC50=2.87005 μM SANGER
KU812 Growth Inhibition Assay IC50=3.05299 μM SANGER
LXF-289 Growth Inhibition Assay IC50=3.12109 μM SANGER
ETK-1 Growth Inhibition Assay IC50=3.20767 μM SANGER
SF126 Growth Inhibition Assay IC50=3.31174 μM SANGER
LC-2-ad Growth Inhibition Assay IC50=3.557 μM SANGER
KNS-42 Growth Inhibition Assay IC50=3.65 μM SANGER
OVCAR-4 Growth Inhibition Assay IC50=3.73433 μM SANGER
PF-382 Growth Inhibition Assay IC50=3.83698 μM SANGER
SH-4 Growth Inhibition Assay IC50=4.25259 μM SANGER
KM12 Growth Inhibition Assay IC50=4.32416 μM SANGER
NB5 Growth Inhibition Assay IC50=4.41864 μM SANGER
KURAMOCHI Growth Inhibition Assay IC50=4.65256 μM SANGER
Becker Growth Inhibition Assay IC50=4.66416 μM SANGER
MV-4-11 Growth Inhibition Assay IC50=4.81344 μM SANGER
KINGS-1 Growth Inhibition Assay IC50=4.82373 μM SANGER
LS-123 Growth Inhibition Assay IC50=5.49684 μM SANGER
SF268 Growth Inhibition Assay IC50=5.61262 μM SANGER
A388 Growth Inhibition Assay IC50=5.63667 μM SANGER
NMC-G1 Growth Inhibition Assay IC50=6.01811 μM SANGER
CGTH-W-1 Growth Inhibition Assay IC50=6.02075 μM SANGER
ES4 Growth Inhibition Assay IC50=6.53074 μM SANGER
SR Growth Inhibition Assay IC50=6.58807 μM SANGER
BB49-HNC Growth Inhibition Assay IC50=6.73206 μM SANGER
KLE Growth Inhibition Assay IC50=6.78377 μM SANGER
HUTU-80 Growth Inhibition Assay IC50=6.98466 μM SANGER
SNU-C2B Growth Inhibition Assay IC50=7.82737 μM SANGER
BB65-RCC Growth Inhibition Assay IC50=7.94904 μM SANGER
QIMR-WIL Growth Inhibition Assay IC50=8.42808 μM SANGER
GDM-1 Growth Inhibition Assay IC50=8.97292 μM SANGER
LC4-1 Growth Inhibition Assay IC50=9.00911 μM SANGER
MLMA Growth Inhibition Assay IC50=9.15006 μM SANGER
EoL-1-cell Growth Inhibition Assay IC50=9.30192 μM SANGER
BOKU Growth Inhibition Assay IC50=9.96466 μM SANGER
EVSA-T Growth Inhibition Assay IC50=10.6568 μM SANGER
D-283MED Growth Inhibition Assay IC50=10.9176 μM SANGER
NB1 Growth Inhibition Assay IC50=11.0242 μM SANGER
RPMI-8402 Growth Inhibition Assay IC50=11.178 μM SANGER
NCI-H1355 Growth Inhibition Assay IC50=11.1806 μM SANGER
NB7 Growth Inhibition Assay IC50=11.3297 μM SANGER
RPMI-6666 Growth Inhibition Assay IC50=12.9567 μM SANGER
697 Growth Inhibition Assay IC50=13.2701 μM SANGER
CTB-1 Growth Inhibition Assay IC50=13.5948 μM SANGER
VA-ES-BJ Growth Inhibition Assay IC50=13.9234 μM SANGER
BE-13 Growth Inhibition Assay IC50=14.3915 μM SANGER
SKM-1 Growth Inhibition Assay IC50=14.4499 μM SANGER
TE-6 Growth Inhibition Assay IC50=14.7591 μM SANGER
LB771-HNC Growth Inhibition Assay IC50=14.7898 μM SANGER
ECC4 Growth Inhibition Assay IC50=17.0277 μM SANGER
ES3 Growth Inhibition Assay IC50=17.4655 μM SANGER
LB647-SCLC Growth Inhibition Assay IC50=17.4949 μM SANGER
NB10 Growth Inhibition Assay IC50=18.5256 μM SANGER
L-540 Growth Inhibition Assay IC50=18.8109 μM SANGER
NCI-H2126 Growth Inhibition Assay IC50=19.51 μM SANGER
HH Growth Inhibition Assay IC50=20.0099 μM SANGER
MPP-89 Growth Inhibition Assay IC50=23.2289 μM SANGER
IST-MEL1 Growth Inhibition Assay IC50=23.8658 μM SANGER
KP-N-YS Growth Inhibition Assay IC50=23.9255 μM SANGER
EC-GI-10 Growth Inhibition Assay IC50=24.5989 μM SANGER
EKVX Growth Inhibition Assay IC50=26.0203 μM SANGER
TGBC1TKB Growth Inhibition Assay IC50=26.434 μM SANGER
Daudi Growth Inhibition Assay IC50=27.0773 μM SANGER
ALL-PO Growth Inhibition Assay IC50=27.081 μM SANGER
NB6 Growth Inhibition Assay IC50=27.488 μM SANGER
ES6 Growth Inhibition Assay IC50=27.9123 μM SANGER
COLO-320-HSR Growth Inhibition Assay IC50=28.0373 μM SANGER
K5 Growth Inhibition Assay IC50=28.1287 μM SANGER
ES1 Growth Inhibition Assay IC50=28.7773 μM SANGER
LC-1F Growth Inhibition Assay IC50=29.7346 μM SANGER
SCLC-21H Growth Inhibition Assay IC50=30.7317 μM SANGER
SK-PN-DW Growth Inhibition Assay IC50=32.5598 μM SANGER
D-247MG Growth Inhibition Assay IC50=32.9773 μM SANGER
TE-5 Growth Inhibition Assay IC50=33.0362 μM SANGER
MONO-MAC-6 Growth Inhibition Assay IC50=33.5048 μM SANGER
LB2518-MEL Growth Inhibition Assay IC50=33.7666 μM SANGER
LOXIMVI Growth Inhibition Assay IC50=33.7928 μM SANGER
NCI-H209 Growth Inhibition Assay IC50=35.144 μM SANGER
A253 Growth Inhibition Assay IC50=35.7429 μM SANGER
HCC1599 Growth Inhibition Assay IC50=36.7053 μM SANGER
EB-3 Growth Inhibition Assay IC50=36.9518 μM SANGER
GOTO Growth Inhibition Assay IC50=37.3224 μM SANGER
SW684 Growth Inhibition Assay IC50=41.8495 μM SANGER
DEL Growth Inhibition Assay IC50=42.0522 μM SANGER
HT-144 Growth Inhibition Assay IC50=42.1676 μM SANGER
TE-9 Growth Inhibition Assay IC50=43.4596 μM SANGER
KARPAS-45 Growth Inhibition Assay IC50=44.3925 μM SANGER
HAL-01 Growth Inhibition Assay IC50=44.5034 μM SANGER
RCC10RGB Growth Inhibition Assay IC50=44.7392 μM SANGER
CP67-MEL Growth Inhibition Assay IC50=45.6241 μM SANGER
NB17 Growth Inhibition Assay IC50=45.6643 μM SANGER
SK-UT-1 Growth Inhibition Assay IC50=45.9464 μM SANGER
JiyoyeP-2003 Growth Inhibition Assay IC50=46.0119 μM SANGER
HCE-4 Growth Inhibition Assay IC50=46.5968 μM SANGER
NCI-H720 Growth Inhibition Assay IC50=46.7682 μM SANGER
KARPAS-422 Growth Inhibition Assay IC50=47.0895 μM SANGER
Ramos-2G6-4C10 Growth Inhibition Assay IC50=47.1622 μM SANGER
HCE-T Growth Inhibition Assay IC50=47.6828 μM SANGER
PSN1 Growth Inhibition Assay IC50=47.7813 μM SANGER
NIH3T3 Function assay Inhibition of human c-Src in NIH3T3 cells, IC50 = 0.0027 μM. 17064066
HEK293 Function assay 1 hr Inhibition of human full length PKMYT1 expressed in HEK293 cells using EFS (247 to 259 residues) as substrate after 1 hr by fluorescence polarization immunoasay, Ki = 0.0398 μM. 29941193
HEK293 Function assay 1 hr Inhibition of human full length PKMYT1 expressed in HEK293 cells using EFS (247 to 259 residues) as substrate after 1 hr by fluorescence polarization immunoasay, IC50 = 0.418 μM. 29941193
Rh30 Antiproliferative assay 48 hrs Antiproliferative activity against human Rh30 cells after 48 hrs by CellTiter-Glo luminescent assay, IC50 = 10.1 μM. 23787099
Huh7 Antiviral assay 2.5 uM 5 days Inhibition of viral spread in Dengue virus-infected human Huh7 cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 5 days by immunofluorescence assay relative to control 17360676
Huh7 Antiviral assay 2.5 uM 6 days Inhibition of viral spread in Dengue virus-infected human Huh7 cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 6 days by immunofluorescence assay relative to control 17360676
Vero Antiviral assay 2.5 uM 4 days Inhibition of viral spread in Dengue virus-infected african green monkey Vero cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 4 days by immunofluorescence assay relative to control 17360676
Vero Antiviral assay 2.5 uM 6 days Inhibition of viral spread in Dengue virus-infected african green monkey Vero cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 6 days by immunofluorescence assay relative to control 17360676
C6/36 Antiviral assay 2.5 uM 4 days Inhibition of viral spread in Dengue virus-infected asian tiger mosquito C6/36 cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 4 days by immunofluorescence assay relative to control 17360676
C6/36 Antiviral assay 2.5 uM 5 days Inhibition of viral spread in Dengue virus-infected asian tiger mosquito C6/36 cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 5 days by immunofluorescence assay relative to control 17360676
Vero Antiviral assay 3 days Antiviral activity against Dengue virus infected in african green monkey Vero cells administered after viral challenge after 3 days by viral plaque assay 17360676
Vero Antiviral assay 2.5 uM 5 days Inhibition of viral spread in Dengue virus-infected african green monkey Vero cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 5 days by immunofluorescence assay relative to control 17360676
Huh7 Antiviral assay 2.5 uM 4 days Inhibition of viral spread in Dengue virus-infected human Huh7 cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 4 days by immunofluorescence assay relative to control 17360676
C6/36 Antiviral assay 2.5 uM 6 days Inhibition of viral spread in Dengue virus-infected asian tiger mosquito C6/36 cells assessed as accumulation of viral envelope protein within perinuclear region at 2.5 uM after 6 days by immunofluorescence assay relative to control 17360676
HEK293 Function assay 0.1 to 1 uM 16 hrs Inhibition of collagen I-induced DDR2 (unknown origin) phosphorylation expressed in HEK293 cells at 0.1 to 1 uM after 16 hrs by Western blotting 26191369
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells 29435139
HEK293 Function assay 0.1 to 1 uM 16 hrs Inhibition of collagen I-induced DDR2 I638F mutant (unknown origin) phosphorylation expressed in HEK293 cells at 0.1 to 1 uM after 16 hrs by Western blotting 26191369
클릭하여 더 많은 세포주 실험 데이터 보기

화학 정보, 보관 및 안정성

분자량 542.03 화학식

C27H32ClN5O5

 보관 (수령일로부터)
CAS 번호 379231-04-6 SDF 다운로드 원액 보관

동의어 N/A Smiles CN1CCN(CC1)CCOC2=CC3=C(C(=C2)OC4CCOCC4)C(=NC=N3)NC5=C(C=CC6=C5OCO6)Cl

용해도

In vitro
배치:

DMSO : 100 mg/mL (184.49 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Ethanol : 100 mg/mL

Water : Insoluble

몰농도 계산기

질량 농도 부피 분자량
희석 계산기 분자량 계산기

In vivo
배치:

생체 내 제형 계산기 (투명한 용액)

1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)

mg/kg g μL

2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

계산 결과:

작업 농도: mg/ml;

DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.

참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.

작용 메커니즘

특징
The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.
Targets/IC50/Ki
c-Src
(Cell-free assay)
2.7 nM
LCK
(Cell-free assay)
<4 nM
c-YES
(Cell-free assay)
4 nM
EGFR (L861Q)
(Cell-free assay)
4 nM
Lyn
(Cell-free assay)
5 nM
EGFR (L858R)
(Cell-free assay)
5 nM
Fyn
(Cell-free assay)
10 nM
FGR
(Cell-free assay)
10 nM
BLK
(Cell-free assay)
11 nM
v-Abl
(Cell-free assay)
30 nM
EGFR
(Cell-free assay)
66 nM
c-Kit
(Cell-free assay)
200 nM
EphA2
(Cell-free assay)
236 nM
시험관 내(In vitro)

Saracatinib (AZD0530)은 또한 c-Yes, Fyn, Lyn, Blk, Fgr, Lck를 포함한 다른 Src 티로신 키나아제 계열 구성원을 IC50 4-10 nM로 강력하게 억제합니다. Src Y530F NIH 3T3를 IC50 80 nM으로 민감하게 억제합니다. 이 화합물은 3차원 콜라겐 매트릭스를 통한 HT1080 세포의 침윤을 유의하게 손상시키고 NBT-II 방광암 세포에서 EGF 유도 세포 확산을 완전히 억제합니다. Y419 인산화 억제를 통해 DU145 및 PC3 세포에서 Src 활성화를 강력하게 억제합니다. LAPC-4, PZ-HPV7 및 RWPE-1 세포에서는 낮은 활성을 보이는 반면 PC3, DU145, CWR22Rv1 및 LNCaP를 포함한 전립선암의 성장을 억제합니다. G1/S에서 세포 주기 정지를 유도하지만 caspase 3 절단은 유도하지 않습니다. 또한 Boyden 챔버에서 DU145 및 PC3 이동을 유의하게 억제합니다. AKT의 강력하고 지속적인 차단을 제공하고 A549 및 Calu-6 세포에서 방사선에 대한 민감도를 향상시킵니다. 활동, 재흡수 및 형성에서 파골세포를 억제합니다. 또한 파골세포 전구체 이동을 가역적으로 방지합니다.

키나아제 분석
키나아제 분석
티로신 키나아제 활성의 IC50은 수용체 및 비수용체 티로신 키나아제 패널의 재조합 촉매 도메인을 사용한 효소 연결 면역흡착 분석(ELISA)으로 측정됩니다(일부 경우에는 촉매 도메인의 일부만 사용됩니다). 이 화합물은 0.001-10 mM 범위로 투여됩니다. 세린/트레오닌 키나아제 패널에 대한 특이성 분석은 32P를 사용한 필터 포획 분석을 사용하여 수행됩니다. 간략하게, 0.5 μL Saracatinib (AZD0530) 또는 대조군(DMSO 단독 또는 pH 3.0 버퍼 대조군)을 포함하는 멀티드롭 384 플레이트를 15 μL의 효소와 펩타이드/단백질 기질과 함께 5분 동안 배양한 후 10 μL의 20 mM Mg-ATP를 첨가하여 반응을 시작합니다. 모든 효소에 대해 최종 농도는 Michaelis 상수(Km)에 근접하게 됩니다. 분석은 실온에서 30분 동안 수행된 후 5 μL의 인산을 첨가하여 종료됩니다. 혼합 후, 웰 내용은 인산을 세척 완충액으로 사용하여 P81 Unifilter 플레이트에 수확됩니다. 그런 다음 IC50이 계산됩니다.
생체 내(In vivo)

Saracatinib (AZD0530)은 Src3T3 동종이식편에서 뛰어난 종양 성장 억제를 보이며 Calu-6, MDA-MB-231, AsPc-1 및 BT474C 이종이식편에서 중간 정도의 성장 지연을 보입니다. 이 화합물은 또한 25mg/kg (경구 투여, 매일) 용량으로 정위 DU145 이종이식 마우스에서 뛰어난 항종양 활성을 보입니다.

참조
  • [4] https://pubmed.ncbi.nlm.nih.gov/19372577/
  • [5] https://pubmed.ncbi.nlm.nih.gov/19216789/
  • [6] https://pubmed.ncbi.nlm.nih.gov/18493848/
  • [7] https://pubmed.ncbi.nlm.nih.gov/19451593/

적용 분야

방법 바이오마커 이미지 PMID
Western blot pY576-FAK / pY861-FAK / FAK pY418 Src / Src / pY410 CAS / CAS / Py421 Cortactin / Cortactin p-Akt / p-mTOR / Akt / mTOR / p-S6 / S6 / p-AMPKα / AMPKα
S1006-WB1
20551056
Growth inhibition assay Cell number
S1006-viability1
24349321

임상시험 정보

(데이터 출처 https://clinicaltrials.gov, 업데이트 날짜 2024-05-22)

NCT 번호 모집 조건 스폰서/협력자 시작일 단계
NCT04598919 Active not recruiting
Idiopathic Pulmonary Fibrosis (IPF)
National Jewish Health|Yale University|Icahn School of Medicine at Mount Sinai|AstraZeneca|National Center for Advancing Translational Sciences (NCATS)|Baylor University|International Center for Health Outcomes and Innovation Research
 November 12 2020 Phase 1|Phase 2
NCT04307953 Recruiting
Fibrodysplasia Ossificans Progressiva
Amsterdam UMC location VUmc|Royal National Orthopaedic Hospital NHS Trust|Klinikum Garmisch-Patenkirchen|University of Oxford|Brigham and Women''s Hospital|AstraZeneca|Innovative Medicines Initiative
 August 5 2020 Phase 2
NCT02085603 Completed
Cancer
Sheffield Teaching Hospitals NHS Foundation Trust|AstraZeneca
 March 2014 Phase 2
NCT01864655 Completed
Alzheimer''s Disease
Stephen M. Strittmatter|National Institute of Neurological Disorders and Stroke (NINDS)|Yale University
 July 2013 Phase 1
NCT01000896 Withdrawn
Cancer|Non Small Cell Lung Cancer|Epithelial Ovarian Cancer
AstraZeneca
 January 2010 Phase 1

기술 지원

취급 설명서

Tel: +1-832-582-8158 Ext:3

다른 문의사항이 있으시면 메시지를 남겨주세요.

이름을 입력해주세요.
이메일을 입력해주세요. 유효한 이메일 주소를 입력해주세요.
저희에게 무엇이든 작성해주세요.

자주 묻는 질문

질문 1:
What is its half-life?

답변:
Based on the following paper, its half-life in vivo is around 40 hours and it reaches its peak level around 2–4 hours after dosing: http://clincancerres.aacrjournals.org/content/16/19/4876.long